BridgeMD
New treatment option for Multiple Myeloma
Official title Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT05336383
What this study is testing
What is Radiation Therapy?
Radiation Therapy is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for multiple myeloma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA CAR-T cell therapy with active disease on the D30+ PET or other imaging scan after CAR-T infusion.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- people must satisfy the following criteria to be enrolled in the study:
- Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF)
- Subject is diagnosed with multiple myeloma
- Subject previously received treatment with standard of care BCMA CAR-T cell therapy
- Day 30 or later PET scan or other imaging scan after CAR-T infusion shows active disease
You likely can't join if
- The presence of any of the following will exclude a subject from enrollment:
- people in whom salvage chemotherapy is planned less than 14 days after the completion of radiation treatment
- Subject is undergoing active treatment for another malignancy other than multiple myeloma
- Pregnant women will be excluded from this study.
See the full eligibility criteria
- people must satisfy the following criteria to be enrolled in the study:
- Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF)
- Subject is diagnosed with multiple myeloma
- Subject previously received treatment with standard of care BCMA CAR-T cell therapy
- Day 30 or later PET scan or other imaging scan after CAR-T infusion shows active disease
- Subject has at least one myeloma lesion (plasmacytoma either in bone or soft tissue) that can be treated with radiation
- Able to provide informed consent
- The presence of any of the following will exclude a subject from enrollment:
- people in whom salvage chemotherapy is planned less than 14 days after the completion of radiation treatment
- Subject is undergoing active treatment for another malignancy other than multiple myeloma
- Pregnant women will be excluded from this study.
The study team makes the final eligibility decision.
Where it's taking place
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Houston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.